Healthcare
Taysha Gene Therapies, Inc.(TSHA)
Live Price
Offline$5.71
+2.33% today
1Y Change
+132.11%
Window
Jun 20, 2025 โ Jun 12, 2026
- Market Cap
- $1.58B
- Revenue Growth
- +17.3%
- EPS Growth
- +5.6%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 20, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Taysha Gene Therapies, Inc. (TSHA) is a Healthcare stock with a market cap of $1.58B and listed on NASDAQ. The stock last traded around $5.71 and up 132.1% across the available one-year price window (Jun 20, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +17.3%, EPS growth of +5.6%, a dividend yield of 0.0%. What stands out right now is revenue +17.3%, EPS +5.6%, free cash flow -15.0% with operating margin -1130.6% and ROIC -34.9%. Valuation already assumes a fairly strong business story at price/sales 162.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TSHA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+17.3% vs +7.6% peer median
Operating Margin
Below sector median
-1130.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 21, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +17.3% and EPS at +5.6%, with operating margin around -1130.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.3% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 21, 2026 | โ | -0.9% | +6.0% | โ |
2026 Mar 19, 2026 | +27.3% | -3.5% | -5.3% | +41.0% |
2025 Nov 4, 2025 | +0.0% | -5.6% | +0.2% | +5.2% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TSHA
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TSHA Max Drawdown
-31.13%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TSHA and SPY.
Company Overview
Taysha Gene Therapies, Inc.
NASDAQ Global Select
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
- Leadership
- Sean Nolan
- IPO Date
- Sep 24, 2020
- Employees
- 73
- Street Address
- 3000 Pegasus Park Drive
- Mailing
- Dallas, TX, 75247
- Region
- Dallas, TX, US
- Reporting Currency
- USD
- Investor Line
- 214 612 0000
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 162.1
- Price/Book
- 8.2
Growth
- Revenue
- +17.3%
- EPS
- +5.6%
- Free Cash Flow
- -15.0%
Profitability
- Gross Margin
- 94.0%
- Operating Margin
- -1130.6%
- Net Margin
- -1115.3%
- ROE
- -56.6%
- ROIC
- -34.9%
Balance Sheet
- Debt/Equity
- 0.07
- Current Ratio
- 12.23
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.